Harrow Enters Into Commercialization Agreement With Samsung Bioepis for Ophthalmology Biosimilars Portfolio

Published on July 18, 2025
NASHVILLE, Tenn. and INCHEON, Korea—Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. to secure exclusive U.S. commercial rights to its ophthalmology biosimilar portfolio, including Byooviz (ranibizumab-nuna), an FDA-approved biosimilar referencing Lucentis (ranibizumab), and Opuviz (aflibercept-yszy), an FDA-approved biosimilar referencing Eylea (aflibercept). Harrow advised that the company will assume full commercial responsibility for these two biosimilars by the end of 2025.
Continue reading on website
Other news

AOA 2025: Innovation and education take forefront at Optometry's Meeting

July 17, 2025
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.

Study underscores importance of upper eyelid meibography in early detection of OSD, among other conditions

July 18, 2025
Study authors Preeya K Gupta, MD, and Paul Karpecki, OD, formulated a case in their literature review for the routine evaluation of the upper eyelid during meibomian gland imaging.